Last October 12th and 13th, 2023, the International Centers for Precision Oncology (ICPO) Foundation has successfully hosted its 3rd ICPO Forum for Theranostics in Precision Oncology physical on the Science Campus in Garching Munich. The Forum is a bi-annual tradition for the German foundation which is working to enable growing numbers of Cancer Patients worldwide to get access to highly effective diagnostics and treatments in Radiomolecular Precision Oncology.
At the occasion of its 3rd Forum, the ICPO Foundation has officially launched its ICPO Academy for Theranostics. The main objective of the Academy programme is to disseminate knowledge in Radiomolecular Precision Oncology in order to improve outcome of a patient treated with radiopharmaceutical therapies, and consequently to ensure sustainable patient access at a global scale.
This was a perfect time for the ICPO Foundation to acknowledge the Public Private Partnership between the Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ) and Isotope Technologies Munich SE (ITM) which made the successful Chinese pilot project of the Academy possible, allowing over 700 users to take part and 340 to obtain certifications. From the inception of the project, the two partners have played a key role in supporting world leading experts from the field to share knowledge and invest time and efforts in creating and contributing to the pilot unique curriculum and content.
The ICPO Academy for Theranostics offers a comprehensive online educational programme, developed by the ICPO Foundation and powered by its global Community of experts. It features over 50 hours of content taught by over 30 leaders and experts. The content is available in different languages. The primary audiences of the ICPO Academy for Theranostics are clinicians, researchers, physicists and radiochemists as well as nurses and technologists, who seek to integrate Radiomolecular Precision Oncology in patient care.
The curriculum by the ICPO Academy for Theranostics has been developed under the guidance of its President, Prof. Richard P. Baum, world leader and pioneer in Nuclear Medicine and Radiomolecular Precision Oncology, together with prominent Pillar Leaders, international experts in their respective field, namely Prof. Vikas Prasad, Prof. Thomas Beyer, Prof. Frank Rösch, Linda Gardner and Josh Mailman. Thanks to their extensive cumulated knowledge and experience as well as personal dedication, they have crafted an exclusive and comprehensive online educational programme that engages over 30 carefully selected Faculty to cover each of the teaching units.
An international certification issued by the ICPO Foundation validates the educational achievements of the participant. Additionally, the ICPO Academy for Theranostics is awaiting accreditation as continued medical education as well as will expand by adding new content developed with and endorsed by prestigious societies, institutions and organisations in the field of Nuclear Medicine globally.
As the ICPO Foundation aims at widening accessibility to education as well as its scalability worldwide, a matching plan is offered to members of the academic community. In practice those may apply for stipends sponsored by third party organisations active in their geography. In return these organizations would reinforce their collaborative and sustainable positioning in the given markets as well as would gain in visibility in terms of talent pool development and further education needs in the field of Radiomolecular Theranostics.
In summary, by officially launching the Academy for Theranostics, the ICPO Foundation is better positioned than ever to support its Community and to enable the global expansion of patient access in Precision Oncology!
All valuable information about the ICPO Academy for Theranostics can be found at www.theranostics.academy. Moreover, to make a donation or become a Member of the ICPO Foundation, as Friend, Supporter or Partner, please visit www.icpo.foundation.
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radionuclide Molecularly Targeted Precision Oncology to support this shift. To scale patient access, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education, and design and process standardization that enables best clinical practice globally. Furthermore, it is the ICPO Foundation’s objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status.
Recently the ICPO foundation has closed collaborations with renowned medical associations such as WARMTH (World Association of Radiopharmaceuticals and Molecular Therapies) and is establishing the ICPO Academy for Theranostics as a globally available e-learning platform.
Learn more at: www.icpo.foundation and www.theranostics.academy